AV-104 will be the first once-daily sublingual tablet for the treatment of Prurigo Nodularis and Chronic Kidney Disease (CKD) – associated Pruritus. AV-104 is a mixed biased GPCR agonist-antagonist, thus reducing the manifestation of Prurigo Nodularis.
Offering Innovative Drug Delivery Technologies for Improved Therapeutics
